Search

Christine Bonzon

from Glendora, CA
Age ~52
Get Report
Also known as:
Comper Bonzon
Phone and address:
223 E Camden St, Glendora, CA 91740
(858) 945-7765
Related to:
Milton Bonzon, 94Dorcas T Bonzon, 83Mark Bonzon, 60Ivan Flett Cowper, 82Dan M Cowper, 56Jeanene L Cowper, 85David D Cowper, 53Ivan M Cowper, 85David E Cowper, 67
Connected to:
Willia BonzulakChristine BooEsha BooJo BooMel Boo, 43Silver S Boo, 78Young K Boo, 60Za C Boo, 82Timothy C Boocher, 69Deborah A Boock, 66

Christine Bonzon Phones & Addresses

  • 223 E Camden St, Glendora, CA 91740 (858) 945-7765
  • Los Angeles, CA
  • 11072 Ocean Air Dr, San Diego, CA 92130 (858) 350-4496
  • Irvine, CA
  • 1249 Linda Rosa Ave, Los Angeles, CA 90041

Publications

Us Patents

Aqueous Compositions And Methods

View page
US Patent:
20110195111, Aug 11, 2011
Filed:
Dec 17, 2010
Appl. No.:
12/972089
Inventors:
B. Michael Butters - Lacey WA, US
John T. Butters - Del Mar CA, US
Christine Bonzon - San Diego CA, US
Marco Gymnopoulos - San Diego CA, US
Mayra Montes Camacho - National City CA, US
Assignee:
NATIVIS, INC. - La Jolla CA
International Classification:
A61K 31/337
A61K 9/127
A61P 35/00
A61K 31/7105
C12N 5/09
G01J 3/44
G01J 3/00
G01R 33/12
B82Y 5/00
US Classification:
424450, 514449, 514 44 A, 435375, 356301, 356 51, 324228, 977773
Abstract:
A method of forming an aqueous composition effective to produce an agent-specific effect on an agent-responsive chemical or biological system, when the composition is added to the system, is disclosed. The composition is formed by exposing an aqueous medium to a low-frequency, time-domain signal derived from the agent, until the aqueous medium acquires a detectable agent activity. Exemplary compositions are formed by exposure to a paclitaxel signal or a signal derived from a therapeutic oligonucleotide, such as GAPDH antisense RNA and PCSK9 antisense RNA. Also disclosed are methods for confirming the activity of the composition, and for preparing and testing the activity of the compositions.

Bispecific And Monospecific Antibodies Using Novel Anti-Pd-1 Sequences

View page
US Patent:
20220204624, Jun 30, 2022
Filed:
Mar 16, 2022
Appl. No.:
17/696799
Inventors:
- Monrovia CA, US
Gregory Moore - Azusa CA, US
John Desjarlais - Pasadena CA, US
Michael Hedvat - Encino CA, US
Christine Bonzon - Los Angeles CA, US
Alex Nisthal - Monrovia CA, US
Umesh Muchhal - Monrovia CA, US
International Classification:
C07K 16/28
A61P 35/00
C07K 16/46
A61K 39/395
Abstract:
The present invention is directed to bispecific, heterodimeric checkpoint antibodies.

Il15/Il15Ralpha Heterodimeric Fc-Fusion Proteins

View page
US Patent:
20220195048, Jun 23, 2022
Filed:
Mar 11, 2022
Appl. No.:
17/692755
Inventors:
- Monrovia CA, US
Rumana Rashid - Azusa CA, US
John Desjarlais - Pasadena CA, US
Rajat Varma - Monrovia CA, US
Christine Bonzon - Los Angeles CA, US
International Classification:
C07K 16/28
C12N 15/63
A61P 35/00
C07K 14/54
C07K 14/715
Abstract:
The present invention is directed to novel IL15/IL15Rα heterodimeric Fc fusion proteins.

Pd-1 Targeted Il-15/Il-15Ralpha Fc Fusion Proteins And Uses In Combination Therapies Thereof

View page
US Patent:
20230055445, Feb 23, 2023
Filed:
Jun 2, 2022
Appl. No.:
17/831197
Inventors:
- Monrovia CA, US
John R. Desjarlais - Pasadena CA, US
Michael Hedvat - Encino CA, US
Suzanne Schubbert - Long Beach CA, US
Christine Bonzon - Los Angeles CA, US
Rumana Rashid - Temple City CA, US
Rajat Varma - Bethesda MD, US
International Classification:
C07K 14/54
C07K 16/28
A61K 39/395
C12N 15/63
Abstract:
The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.

Bispecific Checkpoint Inhibitor Antibodies

View page
US Patent:
20230041377, Feb 9, 2023
Filed:
Sep 28, 2022
Appl. No.:
17/936331
Inventors:
- Monrovia CA, US
Gregory Moore - Azusa CA, US
John Desjarlais - Pasadena CA, US
Michael Hedvat - Encino CA, US
Christine Bonzon - Los Angeles CA, US
Alex Nisthal - Monrovia CA, US
Umesh S. Muchhal - Monrovia CA, US
International Classification:
C07K 16/28
C07K 14/735
C12N 15/861
Abstract:
The present invention is directed to heterodimeric anti-LAG-3×anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.

Bispecific Immunomodulatory Antibodies That Bind Costimulatory And Checkpoint Receptors

View page
US Patent:
20210253706, Aug 19, 2021
Filed:
Apr 16, 2021
Appl. No.:
17/233062
Inventors:
- Monrovia CA, US
Gregory Moore - Azusa CA, US
John Desjarlais - Pasadena CA, US
Michael Hedvat - Encino CA, US
Christine Bonzon - Los Angeles CA, US
International Classification:
C07K 16/28
A61P 35/00
A61P 37/06
Abstract:
The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.

Bispecific Immunomodulatory Antibodies That Bind Costimulatory And Checkpoint Receptors

View page
US Patent:
20210095030, Apr 1, 2021
Filed:
Mar 16, 2020
Appl. No.:
16/820375
Inventors:
- Monrovia CA, US
Gregory Moore - Azusa CA, US
John Desjarlais - Pasadena CA, US
Michael Hedvat - Encino CA, US
Christine Bonzon - Los Angeles CA, US
International Classification:
C07K 16/28
Abstract:
The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.

Il-7-Fc-Fusion Proteins

View page
US Patent:
20210070824, Mar 11, 2021
Filed:
May 15, 2020
Appl. No.:
16/875878
Inventors:
Matthew Bernett - Monrovia CA, US
John Desjarlais - Pasadena CA, US
Suzanne Schubbert - Long Beach CA, US
Christine Bonzon - Los Angeles CA, US
Rajat Varma - Monrovia CA, US
Raphael Clynes - Monrovia CA, US
International Classification:
C07K 14/54
Abstract:
Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.
Control profile
Christine Bonzon from Glendora, CA, age ~52 Get Report